Coherus BioSciences Announces New Employment Inducement Grants
November 10 2021 - 4:15PM
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:
CHRS), today announced that effective Nov. 5, 2021, the
compensation committee of the Company’s board of directors granted
options to purchase an aggregate of 177,500 shares of the common
stock of the Company to newly hired employee with a per share
exercise price of $17.81, the closing trading price on the grant
date. One newly hired Vice President was granted options for 45,000
shares; eleven additional non-officer employees were granted
options to purchase an aggregate of 132,500 shares.
The stock options were granted pursuant to the Coherus
BioSciences, Inc. 2016 Employment Commencement Incentive Plan,
which was approved by the Company’s board of directors in June 2016
under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity
grants to induce new employees to enter into employment with the
Company.
About Coherus BioSciencesCoherus is a
commercial stage biopharmaceutical company with the mission to
increase access to cost-effective medicines that can have a major
impact on patients’ lives and to deliver significant savings to the
health care system. For additional information, please
visit www.coherus.com.
Coherus BioSciences Contact Information:
IR ContactMcDavid StilwellCoherus BioSciences,
Inc.mstilwell@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024